ArticleFrontiers in immunology2025
Serum and urine anti-PLA2R antibody correlation with albuminuria in idiopathic membranous nephropathy.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The value of proteinuria for the administration of rituximab in patients with PLA2R-associated membranous nephropathy: a single-centre retrospective analysis.Annals of medicine · 2026Article
- A machine learning model integrating two-dimensional ultrasound radiomics and clinical parameters for differentiating membranous nephropathy from IgA nephropathy.Journal of ultrasound · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the correlation between anti-phospholipase A2 receptor (PLA2R) levels in serum and urine with clinical parameters, particularly albuminuria, in patients with idiopathic membranous nephropathy (IMN). Methods: We retrospectively analyzed data from 30 patients with biopsy-proven PLA2R-related IMN diagnosed between 2016 and 2022 at two medical centers. Serum and urine anti-PLA2R antibody levels were measured using enzyme-linked immunosorbent assay (ELISA). We assessed the correlation between antibody levels and clinical parameters, including plasma albumin, 24-hour urine protein quantification, and estimated glomerular filtration rate (eGFR). Patients were staged according to the Ehrenreich-Churg classification. Results: Serum anti-PLA2R antibody levels showed a significant negative correlation with plasma albumin (r = -0.469, P < 0.05), whereas urine anti-PLA2R antibody levels exhibited a weak, but significant, positive correlation with 24-hour urine protein excretion (r = 0.362, P = 0.049). Patients with higher serum anti-PLA2R antibody titers had significantly lower plasma albumin levels (20.63 ± 4.79 g/L) compared to those with lower titers (27.71 ± 6.78 g/L) (P < 0.05). Conversely, patients with higher urine anti-PLA2R antibody titers had significantly higher 24-hour urine protein quantification (9.22 ± 4.17 g) compared to those with lower titers (5.32 ± 3.09 g) (P < 0.05). Conclusion: In patients with IMN, serum anti-PLA2R antibody concentrations are inversely associated with plasma albumin, while urine anti-PLA2R antibody levels are positively associated with 24-hour urine protein quantification. These findings suggest that combined assessment of serum and urine anti-PLA2R antibody levels may provide valuable insights into disease activity and albuminuria in IMN. Further studies with larger cohorts are needed to validate these findings and explore their potential clinical implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.